备注：持股数变动有可能因供股、合股、拆股等情况引起，请注意对照实际情况进行辨别。 | 股票名称 | 机构名称 | 性质 | 变动前持股 | 变动后持股 | 持股比 | | --- | --- | --- | --- | --- | --- | | 红星美凯龙 | Taobao Holding | 好仓 | 5318.67 万股 | 4675.21 万股 | 6.31%(最新) | | (01528) | Limited | | | | 7.17%(前次) | | 红星美凯龙 | Alibaba Group Holding | 好仓 | 7637.32 万股 | 6350.40 万股 | 8.57%(最新) | | (01528) | Limited | | | | 10.30%(前次) | | 红星美凯龙 | Taobao China Holding | 好仓 | 5318.67 万股 | 4675.21 万股 | 6.31%(最新) | | (01528) | Limited | | | | 7.17%(前次) | | 北京体育文化 | Hollyview | 好仓 | 2.60 亿股 | 2.62 亿股 ...

智通财经APP获悉，中国星集团(00326)、百心安-B(02185)、地平线(N24028)、红星美凯龙(01528)于 2025年12月16日进行了最新股东权益披露。 | 股票名称 | 机构名称 | 性质 | 变动前持股 | 变动后持股 | 持股比 | | --- | --- | --- | --- | --- | --- | | 中国星集团 | 向华强 | 好仓 | 16.40 亿股 | 16.20 亿股 | 66.71%(最新) | | (00326) | | | | | 67.53%(前次) | | 百心安-B(02185) | Wang Philip Li | 好仓 | 8510.77 万股 | 8511.77 万股 | 36.11%(最新) | | | | | | | 36.11%(前次) | | 中国星集团 | 陈明英 | 好仓 | 16.40 亿股 | 16.20 亿股 | 66.71%(最新) | | (00326) | | | | | 67.53%(前次) | | 地平线(N24028) | 刘芹 | 淡仓 | 1.02 亿股 | 3890.00 万股 | 0.31%(最新) | | | ...

I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國星集團有限公司 呈交日期: 2025年12月1日 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00326 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 2,428,906,151 | | | 0 | | 2,428,906,151 | | 增加 / 減少 (-) | | | | | | | | | | 本月底結存 | | | 2,428,906,151 | | | 0 | | 2,428,906,151 | 第 2 頁 共 10 ...

Core Viewpoint - ST Kelly plans to invest in Dongzhi Medical Technology (Shanghai) Co., Ltd. through equity transfer and subscription of newly registered capital to meet future strategic development needs [1] Company Summary - Dongzhi Medical is focused on the research, production, and sales of regenerative induction products, including regenerative induction biological patches, active cell patches, umbilical cord stem cell preparations, and amniotic membrane gel dressings [1] - The registered capital of Dongzhi Medical is 1.783679 million yuan [1] - Currently, ST Kelly holds 37.9528% of Dongzhi Medical's equity, corresponding to a registered capital of 676,957 yuan [1] Investment Details - As part of the investment, shareholders Shanghai Lisai Management Consulting Partnership (Limited Partnership) and Yuan Zheng will exit Dongzhi Medical [1] - ST Kelly agrees to acquire the equity held by Lisai Management and Yuan Zheng, and will also increase the capital of Dongzhi Medical [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 第 1 頁 共 10 頁 v 1.1.1 FF301 FF301 公司名稱: 中國星集團有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00326 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | HKD | | 0.01 HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 50,000,000,000 | HKD | | 0.01 HKD | | 500, ...

Core Viewpoint - ST Kelly (300326.SZ) reported a decline in operating revenue for Q3 2025, while net profit attributable to shareholders increased slightly, indicating mixed financial performance [1] Financial Performance - Operating revenue for Q3 2025 was 242 million yuan, a year-on-year decrease of 11.84% [1] - Net profit attributable to shareholders was 27.44 million yuan, reflecting a year-on-year increase of 6.26% [1] - Net profit attributable to shareholders after deducting non-recurring gains and losses was 18.35 million yuan, showing a year-on-year decline of 4.51% [1]

Core Insights - ST Kelly (300326.SZ) reported a revenue of 788 million yuan for the first three quarters of 2025, representing a year-on-year growth of 5.03% [1] - The net profit attributable to shareholders reached 71.25 million yuan, marking a year-on-year increase of 27.09% [1] - The non-recurring net profit was 52.11 million yuan, showing a year-on-year growth of 18.07% [1] - The basic earnings per share stood at 0.0994 yuan [1]

Core Viewpoint - ST凯利 (300326.SZ) stated that its main products are currently not applicable to the medical beauty sector and will adhere to information disclosure rules if there are any future developments in this area [1] Group 1 - The company confirmed that its current main products do not cater to the medical beauty industry [1] - The company emphasized its commitment to comply with information disclosure obligations in the event of any relevant product developments [1]

截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國星集團有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00326 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | 本月底法定/ ...

Core Viewpoint - ST凯利 has triggered the buyback conditions outlined in the shareholder agreement with Shanghai Ligetai and has issued a written buyback notice to the relevant parties [1] Group 1 - The company will repurchase its entire 7.0130% stake in Shanghai Ligetai, which corresponds to an investment of RMB 4.5938 million [1] - The total amount for the share transfer to the assignee Ligetai Zhichuang is RMB 152,029,483.02 [1] - The buyback obligation has been agreed upon by the parties involved, with Ligetai Zhichuang assuming the buyback responsibility [1]